Antisense Therapeutics (ASX:ANP) has announced that five patients are now enrolled in the nine patient Phase 2 clinical trial of its immunomodulatory therapy, ATL1102, for Duchenne Muscular Dystrophy (DMD).
The company said four patients are currently being dosed with ATL1102 in the trial with a fifth screened patient having met the eligibility criteria with their dosing scheduled to commence in early February.
No serious adverse safety-related events have been reported to date.
The open-label six-month dosing trial involves patients with DMD aged between 10 and 18. It is being conducted at the neuromuscular centre of the Royal Children’s Hospital in Melbourne. The hospital operates the largest clinic in the southern hemisphere treating children with DMD.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). It is being developed as a novel treatment for the inflammation that exacerbates muscle fibre damage in DMD patients, currently treated with corticosteroids.
The primary endpoints of the trial relate to safety and tolerability. The company said the efficacy of ATL1102 will also be assessed in terms of its effects on markers of inflammation, muscle damage and disease progression.
The company also reported that US-based advocacy group Parent Project Muscular Dystrophy (PPMD) has incorporated details on the ATL1102 for DMD trial on their website.
According to Mark Diamond, CEO of Antisense Therapeutics, “We are very pleased to see the ATL1102 listing by PPMD, the most prominent US DMD advocacy group, as it significantly increases visibility and awareness of ANP’s DMD clinical development activities in the US, the world’s largest pharmaceutical market.”